Melatonin and breast cancer: Cellular mechanisms, clinical studies and future perspectives

Expert Reviews in Molecular Medicine

Volumn 11, Issue , 2009, Pages

  Grant, Stephen G ^a,b   Melan, Melissa A ^c   Latimer, Jean J ^a,b   Witt Enderby, Paula A ^a,b,d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; MELATONIN;

ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; METABOLISM; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BREAST NEOPLASMS; CONTROLLED CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MELATONIN; MODELS, ANIMAL; MODELS, BIOLOGICAL; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 62249177913     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399409000982     Document Type: Review

References (115)

1. Reiter, R.J. (1991) Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine Reviews 12, 151-180
2. Pandi-Perumal, S.R. et al. (2007) Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs 21, 995-1018 (Pubitemid 350136783)
3. Witt-Enderby, P.A. et al. (2003) Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sciences 72, 2183-2198 (Pubitemid 36292142)
4. Poirel, V.J. et al. (2002) MT1 melatonin receptor mRNA expression exhibits a circadian variation in the rat suprachiasmatic nuclei. Brain Research 946, 64-71
5. Gauer, F. et al. (1993) Daily rhythms of melatonin binding sites in the rat pars tuberalis and suprachiasmatic nuclei; evidence for a regulation of melatonin receptors by melatonin itself. Neuroendocrinology 57, 120-126 (Pubitemid 23091896)
6. Gauer, F. et al. (1994) Daily variations in melatonin receptor density of rat pars tuberalis and suprachiasmatic nuclei are distinctly regulated. Brain Research 641, 92-98 (Pubitemid 24087485)
7. Ostrowska, Z. et al. (2003) Influence of lighting conditions on daily rhythm of bone metabolism in rats and possible involvement of melatonin and other hormones in this process. Endocrine Regulations 37, 163-174 (Pubitemid 37413359)
8. Bailey, M.J. et al. (2003) Transcriptional profiling of the chick pineal gland, a photoreceptive circadian oscillator and pacemaker. Molecular Endocrinology 17, 2084-2095 (Pubitemid 37281799)
9. Bailey, M.J. et al. (2004) Transcriptional profiling of circadian patterns of mRNA expression in the chick retina. Journal of Biological Chemistry 279, 52247-52254 (Pubitemid 39656598)
10. Blask, D.E., Sauer, L.A. and Dauchy, R.T. (2002) Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Current Topics in Medicinal Chemistry 2, 113-132
11. Rutter, J., Reick, M. and McKnight, S.L. (2002) Metabolism and the control of circadian rhythms. Annual Review of Biochemistry 71, 307-331 (Pubitemid 34800223)
12. Ravindra, T., Lakshmi, N.K. and Ahuja, Y.R. (2006) Melatonin in pathogenesis and therapy of cancer. Indian Journal of Medical Sciences 60, 523-535 (Pubitemid 44935001)
13. Jasser, S.A., Blask, D.E. and Brainard, G.C. (2006) Light during darkness and cancer: relationships in circadian photoreception and tumor biology. Cancer Causes and Control 17, 515-523
14. Reiter, R.J. et al. (2007) Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Critical Reviews in Oncogenesis 13, 303-328 (Pubitemid 351655045)
15. Shadan, F.F. (2007) Circadian tempo: a paradigm for genome stability? Medical Hypotheses 68, 883-891
16. Valtonen, M. et al. (2005) Effect of melatonin-rich night-time milk on sleep and activity in elderly institutionalized subjects. Nordic Journal of Psychiatry 59, 217-221 (Pubitemid 40946283)
17. Gubin, D.G. et al. (2006) The circadian body temperature rhythm in the elderly: effect of single daily melatonin dosing. Chronobiology International 23, 639-658 (Pubitemid 43879810)
18. Marks, F., Furstenberger, G. and Muller-Decker, K. (2007) Tumor promotion as a target of cancer prevention. Recent Results in Cancer Research 174, 37-47
19. Panzer, A. and Viljoen, M. (1997) The validity of melatonin as an oncostatic agent. Journal of Pineal Research 22, 184-202 (Pubitemid 127499119)
20. Vijayalaxmi et al. (2002) Melatonin: from basic research to cancer treatment clinics. Journal of Clinical Oncology 20, 2575-2601 (Pubitemid 34525746)
21. Cos, S. and Sanchez-Barcelo, E.J. (2000) Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histology and Histopathology 15, 637-647 (Pubitemid 30218860)
22. Cos, S. and Sanchez-Barcelo, E.J. (2000) Melatonin and mammary pathological growth. Frontiers in Neuroendocrinology 21, 133-170 (Pubitemid 30228502)
23. Lenoir,V. et al. (2005) Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat. Breast Cancer Research 7, R470-476
24. Blask, D.E. et al. (2005) Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Research 65, 11174-11184 (Pubitemid 41713389)
25. Cos, S. and Blask, D.E. (1994) Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. Journal of Pineal Research 17, 25-32
26. Baturin, D.A. et al. (2001) The effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression. Neuroendocrinology Letters 22, 441-447 (Pubitemid 34026306)
27. Rato, A.G. et al. (1999) Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB Journal 13, 857-868
28. Kiefer, T. et al. (2002) Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Research and Treatment 71, 37-45 (Pubitemid 34121815)
29. Sanchez-Barcelo, E.J. et al. (2005) Melatoninestrogen interactions in breast cancer. Journal of Pineal Research 38, 217-222
30. del Rio, B. et al. (2004) Melatonin, an endogenousspecific inhibitor of estrogen receptor alpha via calmodulin. Journal of Biological Chemistry 279, 38294-38302
31. Satomura, K. et al. (2007) Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo. Journal of Pineal Research 42, 231-239 (Pubitemid 46365059)
32. Sanchez-Hidalgo, M. et al. (2007) Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: implications for osteoblast differentiation and osteoporosis. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 292, R2208-2215 (Pubitemid 47080681)
33. Schuster, C. et al. (2005) The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. Journal of Neuroendocrinology 17, 170-178 (Pubitemid 40553016)
34. Johnston, J.D. et al. (2006) Regulation of MT melatonin receptor expression in the foetal rat pituitary. Journal of Neuroendocrinology 18, 50-56
35. Radio, N.M., Doctor, J.S. and Witt-Enderby, P.A. (2006) Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. Journal of Pineal Research 40, 332-342
36. Sainz, R.M. et al. (2005) Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 63, 29-43 (Pubitemid 40365388)
37. Bellon, A. et al. (2007) Melatonin induces neuritogenesis at early stages in N1E-115 cells through actin rearrangements via activation of protein kinase C and Rho-associated kinase. Journal of Pineal Research 42, 214-221 (Pubitemid 46365057)
38. Moriya, T. et al. (2007) Melatonin influences the proliferative and differentiative activity of neural stem cells. Journal of Pineal Research 42, 411-418 (Pubitemid 46581666)
39. Jimenez-Jorge, S. et al. (2005) Melatonin synthesis and melatonin-membrane receptor (MT1) expression during rat thymus development: role of thepineal gland. Journal of PinealResearch39, 77-83 (Pubitemid 40966466)
40. Witt-Enderby, P.A. et al. (2006) Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. Journal of Pineal Research 41, 297-305 (Pubitemid 44498215)
41. Bondi, C.D. et al. (2008) MT1 melatonin receptor internalization underlies melatonin-induced morphologic changes in Chinese hamster ovary cells and these processes are dependent on Gi proteins, MEK 1/2 and microtubule modulation. Journal of Pineal Research 44, 288-298 (Pubitemid 351392943)
42. Jarzynka, M.J. et al. (2006) Modulation of melatonin receptors and G-protein function by microtubules. Journal of Pineal Research 41, 324-336 (Pubitemid 44498218)
43. Witt-Enderby, P.A. and Dubocovich, M.L. (1996) Characterization and regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells. Molecular Pharmacology 50, 166-174 (Pubitemid 26250088)
44. Brydon, L. et al. (1999) Dual signaling of human Mel1amelatonin receptors via G(i2), G(i3), and G(q/ 11) proteins. Molecular Endocrinology 13, 2025-2038 (Pubitemid 30637264)
45. Cini, G. et al. (2005) Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: a molecular basis for melatonininduced oncostatic effects. Journal of Pineal Research 39, 12-20 (Pubitemid 40966457)
46. Dai, J. et al. (2002) Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells. Journal of Pineal Research 32, 112-119 (Pubitemid 34289589)
47. Martinez-Campa, C. et al. (2006) Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. Journal of Pineal Research 40, 291-296
48. Roy, D. et al. (2001) Cyclical regulation of GnRH gene expression in GT1-7 GnRH-secreting neurons by melatonin. Endocrinology 142, 4711-4720 (Pubitemid 33022346)
49. Cos, S. et al. (2005) Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. Journal of Pineal Research 38, 136-142 (Pubitemid 40293239)
50. Cos, S. et al. (2006) Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. International Journal of Cancer 118, 274-278 (Pubitemid 41779064)
51. Reiter, R.J. et al. (2007) Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochimica Polonica 54, 1-9 (Pubitemid 46481811)
52. Tan, D.X. et al. (2007) Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. Journal of Pineal Research 43, 317-320
53. Nosjean, O. et al. (2000) Identification of the melatonin-binding site MT3 as the quinone reductase 2. Journal of Biological Chemistry 275, 31311-31317
54. Nosjean, O. et al. (2001) Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochemical Pharmacology 61, 1369-1379 (Pubitemid 32452352)
55. Dziegiel, P., Podhorska-Okolow, M. and Zabel, M. (2008) Melatonin: adjuvant therapy of malignant tumors. Medical Science Monitor 14, RA64-70 (Pubitemid 351679883)
56. Pawlikowski, M., Winczyk, K. and Karasek, M. (2002) Oncostatic action of melatonin: facts and question marks. Neuroendocrinolology Letters 23 Suppl 1, 24-29 (Pubitemid 34495378)
57. Moss, R.W. (2004) Cancer and complementary and alternative medicine in Italy: personal observations and historical considerations. Integrative Cancer Therapies 3, 173-188
58. Lissoni, P. et al. (1991) Modulation of interleukin-2- induced macrophage activation in cancer patients by the pineal hormone melatonin. Journal of Biological Regulators and Homeostatic Agents 5, 154-156
59. Carrillo-Vico, A. et al. (2003) Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor. FASEB Journal 17, 755-757
60. Leon-Blanco, M.M. et al. (2003) Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. Journal of Pineal Research 35, 204-211 (Pubitemid 37100399)
61. Reiter, R.J. et al. (1999) Augmentation of indices of oxidative damage in life-long melatonin-deficient rats. Mechanisms of Ageing and Development 110, 157-173 (Pubitemid 29486734)
62. Morioka, N., Okatani, Y. and Wakatsuki, A. (1999) Melatoninprotects against age-relatedDNAdamage in the brains of female senescence-accelerated mice. Journal of Pineal Research 27, 202-209 (Pubitemid 29515430)
63. Anisimov, V.N. et al. (2003) Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice. Experimental Gerontology 38, 449-461 (Pubitemid 36379081)
64. Vinogradova, I.A. et al. (2007) [Effect of light regimens and melatonin on the homeostasis, life span and development of spontaneous tumors in female rats.] Advances in Gerontology 20, 40-47 [Article in Russian]
65. Braeckman, B.P., Demetrius, L. and Vanfleteren, J.R. (2006) The dietary restriction effect in C. elegans and humans: is the worm a onemillimeter human? Biogerontology 7, 127-133 (Pubitemid 44151619)
66. Bartsch, C. and Bartsch, H. (2006) The anti-tumor activity of pineal melatonin and cancer enhancing life styles in industrialized societies. Cancer Causes and Control 17, 559-571
67. Davis, S. and Mirick, D.K. (2006) Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. Cancer Causes and Control 17, 539-545
68. Moriya, T. et al. (2007) Correlative association between circadian expression of mousePer2 gene and the proliferation of the neural stem cells. Neuroscience 146, 494-498 (Pubitemid 46617071)
69. Gery, S. et al. (2005) Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 106, 2827-2836 (Pubitemid 41510760)
70. Chen, S.T. et al. (2005) Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26, 1241-1246
71. Migliore, L. and Coppede, F. (2002) Genetic and environmental factors in cancer and neurodegenerative diseases. Mutation Research 512, 135-153 (Pubitemid 35446305)
72. Nogues, M.R. et al. (2006) Melatonin reduces oxidative stress in erythrocytes and plasma of senescence-accelerated mice. Journal of Pineal Research 41, 142-149 (Pubitemid 44141749)
73. Loft, S. and Poulsen, H.E. (1996) Cancer risk and oxidative DNA damage in man. Journal of Molecular Medicine 74, 297-312 (Pubitemid 26195901)
74. Schernhammer, E.S. et al. (2004) Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiology Biomarkers and Prevention 13, 936-943 (Pubitemid 38756703)
75. Megdal, S.P. et al. (2005) Night work and breast cancer risk: a systematic review and meta-analysis. European Journal of Cancer 41, 2023-2032 (Pubitemid 41557687)
76. Schernhammer, E.S. and Hankinson, S.E. (2005) Urinary melatonin levels and breast cancer risk. Journal of theNational Cancer Institute 97, 1084-1087
77. Travis, R.C. et al. (2004) Melatonin and breast cancer: a prospective study. Journal of the National Cancer Institute 96, 475-482 (Pubitemid 38443651)
78. Blask, D.E. (1993) Melatonin in oncology. In Melatonin: Biosynthesis, Physiological Effects and ClinicalApplications (Yu,H.-S. andReiter,R.J., eds), pp. 447-476, CRC Press, Boca Raton, USA
79. Tarquini, B. et al. (1994) Daytime circulating melatonin levels in smokers. Tumori 80, 229-232 (Pubitemid 24266160)
80. Bartsch, C. et al. (1994) Diminished pineal function coincides with disturbed circadian endocrine rhythmicity in untreated primary cancer patients. Consequence of premature aging or of tumor growth? Annals of the New York Academy of Sciences 719, 502-525 (Pubitemid 24200001)
81. Bartsch, C. et al. (1997) Nocturnal urinary 6-sulfatoxymelatonin and proliferating cell nuclear antigen-immunopositive tumor cells show strong positive correlations in patients with gastrointestinal and lung cancer. Journal of Pineal Research 23, 90-96 (Pubitemid 127731743)
82. Blask, D.E. (1997) The melatonin rhythm in cancer patients. In Melatonin in Psychiatric and Neoplastic Disorders (Shafii, M. and Shafii, S.L., eds), pp. 243-260, American Psychiatric Press, Washington, D.C., USA
83. Kusmartsev, S. and Gabrilovich, D.I. (2006) Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer and Metastasis Reviews 25, 323-331 (Pubitemid 44922353)
84. Kawanishi, S. and Hiraku, Y. (2006) Oxidative and nitrative DNA damage as biomarker for carcinogenesis with special reference to inflammation. Antioxidants and Redox Signalling 8, 1047-1058 (Pubitemid 44036521)
85. Chen, R. et al. (2007) Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. American Journal of Reproductive Immunology 57, 93-107 (Pubitemid 46099804)
86. Burch, J.B. et al. (2007) Melatonin and estrogen in breast cyst fluids. Breast Cancer Research and Treatment 103, 331-341 (Pubitemid 46944505)
87. Maestroni, G.J. and Conti, A. (1996) Melatonin in human breast cancer tissue: association with nuclear grade and estrogen receptor status. Laboratory Investigation 75, 557-561 (Pubitemid 26346805)
88. Poeggeler, B. (2005) Melatonin, aging, and age-related diseases: perspectives for prevention, intervention, and therapy. Endocrine 27, 201-212
89. Poeggeler, B. et al. (1993) Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. Journal of Pineal Research 14, 151-168 (Pubitemid 23253014)
90. Brozmanova, J., Dudas, A. and Henriques, J.A. (2001) Repair of oxidative DNA damage-an important factor reducing cancer risk. Minireview. Neoplasma 48, 85-93 (Pubitemid 32428537)
91. Becr VII Phase 2 (2006) Health Risks fromExposure to Low Levels of Ionizing Radiation, National Academies Press, Washington, D.C., USA
92. Vesnushkin, G.M. et al. (2006) Dose-dependent inhibitory effect of melatonin on carcinogenesis induced by benzo[a]pyrene in mice. Journal of Experimental and Clinical Cancer Research 25, 507-513 (Pubitemid 46166764)
93. Lissoni, P. et al. (1996) Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin. Supportive Care in Cancer 4, 313-316 (Pubitemid 126469655)
94. Norsa, A. and Martino, V. (2007) Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapypretreated patients with advanced lung adenocarcinoma and low performance status. Cancer Biotherapy and Radiopharmaceuticals 22, 50-55
95. Lissoni, P. et al. (1995) A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia. Oncology 52, 360-362
96. Lissoni, P. et al. (1996) The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia. Recenti Progressi in Medicina 87, 582-585
97. Lissoni, P. et al. (1996) Is there a role for melatonin in the treatment of neoplastic cachexia? European Journal of Cancer 32A, 1340-1343 (Pubitemid 26246707)
98. Cos, S. et al. (2006) Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detection and Prevention 30, 118-128 (Pubitemid 43766230)
99. Treilleux et al. (1997) Human estrogen receptor (ER) gene promoter-P1: estradiol-independent activity and estradiol inducibility in ER+ and ER-cells. Molecular Endocrinology 11, 1319-1331 (Pubitemid 28041338)
100. Cunat, S., Hoffmann, P. and Pujol, P. (2004) Estrogens and epithelial ovarian cancer. Gynecologic Oncology 94, 25-32 (Pubitemid 38950494)
101. Naderi, A. et al. (2007) BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Research 67, 6725-6736 (Pubitemid 47105519)
102. Tiligada, E. (2006) Chemotherapy: induction of stress responses. Endocrine-Related Cancer 13 Suppl 1, S115-124
103. Mills, E. et al. (2005) Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. Journal of Pineal Research 39, 360-366
104. Vijayalaxmi et al. (2004) Melatonin as a radioprotective agent: a review. International Journal of Radiation Oncology, Biology, Physics 59, 639-653 (Pubitemid 38748729)
105. Lissoni, P. (2007) Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathologie-Biologie 55, 201-204
106. Jonsson, G., Staaf, J., Olssen, E., Heidenblad, M., Vallon-Christersson, J., Osoegawa, K., de Jong, P., Oredsson, S., Ringr, M., Hoglund, M., and Borg, A. (2007) High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 46, 543-558 (Pubitemid 46649569)
107. Crespo, D. et al. (1994) Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. Journal of Pineal Research 16, 215-222
108. Hill, S.M. and Blask, D.E. (1988) Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Research 48, 6121-6126 (Pubitemid 18266811)
109. Wenger, S.L. et al. (2004) Comparison of established cell lines at different passages by karyotype and comparative genomic hybridization. Bioscience Reports 24, 631-639 (Pubitemid 41297983)
110. Klein, A. et al. (2006) Different mechanisms of mitotic instability in cancer cell lines. International Journal of Oncology 29, 1389-1396
111. Chatterjee, S.K. and Zetter, B.R. (2005) Cancer biomarkers: knowing the present and predicting the future. Future Oncology 1, 37-50
112. Wang, Y. et al. (2007) Gene expression profiles and prognostic markers for primary breast cancer. Methods in Molecular Biology 377, 131-138 (Pubitemid 350183369)
113. Stemke-Hale, K. et al. (2006) Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein. Current Oncology Reports 8, 484-491 (Pubitemid 44697778)
114. Reiter, R.J. and Tan, D.X. (2003) What constitutes a physiological concentration of melatonin? Journal of Pineal Research 34, 79-80 (Pubitemid 36140362)
115. Aust, S. et al. (2005) Biotransformation of melatonin in human breast cancer cell lines: role of sulfotransferase 1A1. Journal of Pineal Research 39, 276-282 (Pubitemid 41337808)